Relmada Therapeutics sinks 80% as depression therapy fails

Relmada Therapeutics

13/10/2022 12:46

** Relmada Therapeutics shares  RLMD.O  sink ~80% premarket
    ** Co's late stage trial for experimental single drug
therapy, REL-1017, in treating major depressive disorder (MDD)
fails to meet main goal of showing significant improvement in
depression symptoms compared to placebo  urn:newsml:reuters.com:*:nPnbMyH5Ha
    ** Co says will continue enrolling patients in two ongoing
late-stage studies evaluating REL-1017 as a potential MDD
treatment
    ** Up to Wednesday's close, stock up 40.7%
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))